Cattle & Porcine/Swine Reproductive Diseases Market

The global cattle & porcine/swine reproductive diseases market is projected to reach USD 975.8 million by 2029 from USD 758.2 million in 2024 at a CAGR of 5.2%.

The Cattle & porcine/swine reproductive diseases market encompasses a range of products and services designed for the diagnosis, prevention, and treatment of reproductive diseases in cattle and pigs. These conditions significantly impact fertility, pregnancy, and overall reproductive health, which in turn affects livestock productivity and profitability. The market includes diagnostic tools, veterinary pharmaceuticals, and nutritional supplements specifically targeting diseases such as Brucellosis, Leptospirosis, Porcine Reproductive and Respiratory Syndrome (PRRS), and Bovine Viral Diarrhea (BVD). Effective prevention and management of these diseases are critical to avoid substantial economic losses and ensure the sustained productivity of livestock.

To know about the assumptions considered for the study download the pdf brochure

The prominent players of global Cattle & porcine/swine reproductive diseases market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmBH (Germany), Virbac (France), Elanco Animal Health Incorporated (US), Vetoquinol S.A. (France), Ceva Santé Animale (France), Idexx Laboratories (US), Thermo Fisher Scientific Inc. (US), Biochek Smart Veterinary Diagnostics (Netherlands), Ring Biotechnology Co Ltd. (China), Sequent Scientific Limited (India), Hipra (Spain), Qiagen N.V. (Germany), Innovative Diagnostics (France), Colorado Serum Company (US), Indian Immunologicals Ltd (US), Refit Animal Care (India), Calier (US), Megacor Diagnostik GmBH (Austria), Vetanco (Brazil), Biogenesis Bago (Argentina), Advacare Pharma (US), Bio-X Diagnostics S.A. (Belgium), Pax Healthcare (India). These companies adopted strategies such as product launches, partnerships, acquisitions, and expansions to strengthen their presence in the endoscopy equipment market.

Zoetis Inc. (US)

Zoetis Inc. is a leading global company in animal health, specializing in the discovery, development, manufacturing, and commercialization of vaccines and medicines for livestock and companion animals. The company operates through three segments: Companion Animals, Livestock, and Contract Manufacturing & Human Health. Zoetis' Livestock segment offers products for reproductive diseases in cattle and porcine. With operations in 70 countries, Zoetis' products are distributed across over 120 countries. Key subsidiaries include Allabing de Mexico, S.A. de C.V., Alpharma Animal Health Company (US), and Jilin Pfizer Guoyuan Animal Health Co., Ltd. (China), among others. The company is divided into four geographic regions: the US; Europe, Africa, and the Middle East; Canada and Latin America; and the Asia Pacific. In September 2022, Zoetis acquired Jurox Pty Limited, an Australian animal health company. In March 2024, it announced the acquisition of a 21-acre manufacturing site in Melbourne to expand vaccine development and manufacturing capabilities.

Merck & Co., Inc. (US)

Merck & Co., Inc. is a global healthcare leader providing innovative solutions across pharmaceuticals, vaccines, biologic therapies, and animal health products. The company operates through two main segments: Pharmaceuticals and Animal Health. The Animal Health division, branded as MSD Animal Health outside the US and Canada, supplies veterinary pharmaceuticals, vaccines, and health management solutions to veterinarians, farmers, pet owners, and governments. Merck operates in over 140 countries and has 25 manufacturing sites across the Americas, Europe, and Asia Pacific. Its robust R&D network includes 16 centers in countries such as the US, Germany, India, and Japan. Key subsidiaries include MSD Animal Health in the UAE, Switzerland, and Germany, as well as operations in China and Canada. In June 2021, Merck bolstered its cattle health technology by acquiring LIC Automation Ltd. from New Zealand's Livestock Improvement Corporation, enhancing its global presence in animal health technology.

Boehringer Ingelheim International GmBH (Germany)

Boehringer Ingelheim International GmbH is a prominent pharmaceutical company specializing in prescription medicines, healthcare products, and pharmaceuticals for humans and animals. The company is organized into three segments: Human Pharma, Animal Health, and Other Sales. Its Animal Health division offers a range of products, including parasiticides for both food-producing and companion animals. The company operates its reproductive disease-related products in the U.S. through its subsidiary, Boehringer Ingelheim Animal Health USA Inc. The company has 146 subsidiaries worldwide, such as Boehringer Ingelheim Pharmaceuticals, Inc. (US), Boehringer Ingelheim Backmittel GmbH (Germany), Boehringer Ingelheim Pty. Ltd. (Australia), and others in Italy, Japan, Brazil, and Mexico. In November 2022, The company launched the PRRS Knowledge Manual, a comprehensive handbook summarizing over 25 years of research and best practices for controlling porcine reproductive and respiratory syndrome virus (PRRSV).

Related Reports:

Cattle & Porcine/Swine Reproductive Diseases Market by Product (Diagnostics (ELISA, PCR, Rapid Antigen Testing), Pharmaceuticals (Vaccines), Supplements, Animal Type, Disease (BVD, PRRS, Leptospirosis, Brucellosis), End User - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]